Literature DB >> 2331413

Five cases demonstrating the distinctive behavioural features of chromosome deletion 17(p11.2 p11.2) (Smith-Magenis syndrome).

A F Colley1, M A Leversha, L E Voullaire, J G Rogers.   

Abstract

Children with hyperactivity and self-destructive behaviour present a difficult problem for parents and paediatricians. The syndrome described by Smith and Magenis is due to a deletion on the short arm of chromosome 17: del(17)(p11.2 p11.2). Clinical manifestations include brachycephaly and a flat mid-face; brachydactyly; short, broad hands; mental retardation; and aberrant behaviour, including hyperactivity. We report on five children, and review the literature on a newly recognised syndrome in which the behaviour manifestations may precede and often overshadow the learning disabilities and unusual appearance. In addition, we have found sleep disturbance to be a major feature in our patients.

Entities:  

Mesh:

Year:  1990        PMID: 2331413     DOI: 10.1111/j.1440-1754.1990.tb02372.x

Source DB:  PubMed          Journal:  J Paediatr Child Health        ISSN: 1034-4810            Impact factor:   1.954


  12 in total

1.  Molecular analyses of 17p11.2 deletions in 62 Smith-Magenis syndrome patients.

Authors:  R C Juyal; L E Figuera; X Hauge; S H Elsea; J R Lupski; F Greenberg; A Baldini; P I Patel
Journal:  Am J Hum Genet       Date:  1996-05       Impact factor: 11.025

2.  Brief report: cognitive and behavioral profiles in persons with Smith-Magenis syndrome.

Authors:  E M Dykens; B M Finucane; C Gayley
Journal:  J Autism Dev Disord       Date:  1997-04

3.  Physical mapping of microdeletions of the chromosome 17 short arm associated with Smith-Magenis syndrome.

Authors:  A Moncla; L Piras; O F Arbex; F Muscatelli; M G Mattei; J F Mattei; M Fontes
Journal:  Hum Genet       Date:  1993-02       Impact factor: 4.132

4.  Molecular analysis of deletion (17)(p11.2p11.2) in a family segregating a 17p paracentric inversion: implications for carriers of paracentric inversions.

Authors:  S P Yang; S I Bidichandani; L E Figuera; R C Juyal; P J Saxon; A Baldini; P I Patel
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

Review 5.  Management of Self-injurious Behaviors in Children with Neurodevelopmental Disorders: A Pharmacotherapy Overview.

Authors:  Ashley Sabus; James Feinstein; Patrick Romani; Edward Goldson; Allison Blackmer
Journal:  Pharmacotherapy       Date:  2019-03-27       Impact factor: 4.705

6.  Functional and cellular characterization of human Retinoic Acid Induced 1 (RAI1) mutations associated with Smith-Magenis Syndrome.

Authors:  Paulina Carmona-Mora; Carolina A Encina; Cesar P Canales; Lei Cao; Jessica Molina; Pamela Kairath; Juan I Young; Katherina Walz
Journal:  BMC Mol Biol       Date:  2010-08-25       Impact factor: 2.946

7.  The human homologue of the Drosophila melanogaster flightless-I gene (flil) maps within the Smith-Magenis microdeletion critical region in 17p11.2.

Authors:  K S Chen; P H Gunaratne; J D Hoheisel; I G Young; G L Miklos; F Greenberg; L G Shaffer; H D Campbell; J R Lupski
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

8.  Neurodevelopment of children under 3 years of age with Smith-Magenis syndrome.

Authors:  Pamela L Wolters; Andrea L Gropman; Staci C Martin; Michaele R Smith; Hanna L Hildenbrand; Carmen C Brewer; Ann C M Smith
Journal:  Pediatr Neurol       Date:  2009-10       Impact factor: 3.372

9.  Molecular analysis of the Smith-Magenis syndrome: a possible contiguous-gene syndrome associated with del(17)(p11.2).

Authors:  F Greenberg; V Guzzetta; R Montes de Oca-Luna; R E Magenis; A C Smith; S F Richter; I Kondo; W B Dobyns; P I Patel; J R Lupski
Journal:  Am J Hum Genet       Date:  1991-12       Impact factor: 11.025

10.  Mouse models of genomic syndromes as tools for understanding the basis of complex traits: an example with the smith-magenis and the potocki-lupski syndromes.

Authors:  P Carmona-Mora; J Molina; C A Encina; K Walz
Journal:  Curr Genomics       Date:  2009-06       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.